Study Confirms Safety of Paracetamol During Pregnancy
A recent comprehensive review suggests that taking paracetamol while pregnant is safe and does not increase the risk of autism, ADHD, or other developmental issues in children. This research aims to ease concerns among expectant mothers about the medication’s safety.
The study’s findings stand in stark contrast to the claims made by former US President Donald Trump last year, who stated that paracetamol “is no good” and advised pregnant women to avoid it. His remarks drew criticism from medical professionals worldwide, and experts believe that this latest review, published in a Lancet journal, should put any safety debates to rest.
Despite these reassuring findings, US health officials still convey that “many experts” have voiced concerns about the drug’s use during pregnancy.
Trump’s earlier assertions about paracetamol—or Tylenol, as it is known in the US—linking it to autism sparked considerable confusion and alarm among women and medical experts, which led to the initiation of this new study.
This review, highlighted in The Lancet Obstetrics, Gynaecology & Women’s Health, examined 43 high-quality studies involving numerous pregnancies. The researchers compared pregnancies where women had taken paracetamol against those who had not, allowing them to account for varying genetic and environmental factors, thus strengthening their conclusions.
According to lead study author Professor Asma Khalil, there has been no evidence to suggest that paracetamol increases the risk of autism. She emphasized that the findings reinforce the guidance from several major health organizations about the safety of this common medication during pregnancy.
Furthermore, any previous correlations between paracetamol use and autism risk are likely attributable to other variables, rather than being a direct result of the medication itself. Khalil noted the importance of paracetamol as a first-line recommendation for pain or fever relief in pregnant women, stating that neglecting to manage pain or high temperatures might risk more severe complications, like miscarriage or developmental issues in fetuses.
Medical experts who were not directly involved in the research expressed optimism about its implications. Professor Grainne McAlonnan from King’s College London highlighted that expectant mothers should not have to stress over whether a commonly used painkiller could adversely affect their child’s health.
Independent assessments of the study commended its rigorous methodology, as said by Professor Ian Douglas from the London School of Hygiene and Tropical Medicine. He pointed out that excluding lower-quality studies, which often failed to consider varying maternal health backgrounds, made the research stronger overall. Professor Jan Haavik, a molecular neuroscientist from the University of Bergen, stated that the study provides robust evidence against any link between paracetamol use during pregnancy and increased risk of autism or ADHD, suggesting that this matter is likely settled.
Nonetheless, U.S. health authorities remain cautious. A spokesman from the Department of Health and Human Services mentioned ongoing concerns voiced by many professionals regarding acetaminophen’s use in pregnancy. For instance, a review led by Dr. Andrew Baccarelli from Harvard in August noted potential links between acetaminophen use and increased risks of autism and ADHD, prompting advisories against heavy or prolonged use.
In a speech, Trump ordered that healthcare providers should refrain from prescribing paracetamol to pregnant women, a statement that stirred further debate. The FDA had previously issued a letter urging caution while recognizing paracetamol as the sole approved medication for fever management during pregnancy.
Thus, while the recent study brings reassurance to many, the conversations around paracetamol’s use in pregnancy remain complex, intertwining cautious advice with reassuring research.
